Major mechanistic differences explain the higher clot lysis potency of reteplase over alteplase: Lack of fibrin binding is an advantage for bolus application of fibrin-specific thrombolytics

Fibrinolysis and Proteolysis

Volumn 11, Issue 3, 1997, Pages 129-135

  Fischer, S ^a   Kohnert, U ^a  

^a Biochemical Research Center Penzberg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; RETEPLASE;

ARTICLE; BLOOD CLOT LYSIS; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; FIBRIN CLOT; PRIORITY JOURNAL;

EID: 0030714055     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80057-4     Document Type: Article

References (27)

1. Kohnert U, Rudolph R, Verheijen J H, Weening-Verhoeff E J D, Stern A, Opitz U, Martin U, Lill H, Prinz H, Lechner M, Kresse G-B, Buckel P, Fischer S. Biochemical properties of the kringle 2 and the protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Protein Engineering 1992; 5: 93-100.
2. Müller W, Haerer W, Ellbrück D, Martin U, König R, Seifried E. Pharmacokinetics and effects on the hemostatic system of bolus application of a novel recombinant plasminogen activator in AMI patients. Fribrinolysis 1992; 6 (suppl. 2): 26.
3. Seifried E. Klinische und biochemische Zielsetzung bei der Thrombolysetherapie mit Neothrombolytika. Hämostaseologie 1988; 8: 199-213.
4. Martin U, Fischer S, Kohnert U, Rudolph R, Sponer G, Stern A, Strein K. Coronary thrombolytic properties of a novel plasminogen activator (BM 06.022) in a canine model. J Cardiovascular Pharmacology 1991; 18: 111-119.
5. Smalling R W, Bode C, Kalbfleisch J, Sen S, Limbourg P, Forycki F, Habib G, Feldman R, Hohnloser S, Seals A, the RAPID investigators. More rapid, complete and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardical infarction. Circulation 1995; 91: 2725-2732.
6. van Zonneveld A J, Veerman H, Pannekoek H. On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Proc Natl Acad Sci, USA 1986; 83: 4670-4674.
7. Hoylaerts M, Rijken D C, Lijnen H R, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. J Biol Chem 1982; 257: 2912-2919.
8. Topol E, the GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. New Engl J Med 1993; 329: 673-682.
9. Yusef S, Anand S, Arezum A, Flather M, Coutinho M. Treatment of acute myocardial infarction. Overview of randomized clinical trials. Eur Heart J 1996; 17 (Suppl F): 16-29.
10. Rijken D C, Hoylaerts M, Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 1982; 257: 2920-2925.
11. Kohnert U, Hellerbrand K, Martin U, Stern A, Popp F, Fischer S. The recombinant Escherichia coli-derived protease domain of tissue-type plasminogen activator is a potent and fibrin specific fibrinolytic agent. Fibrinolysis 1996; 10: 93-102.
12. Kohnert U, Wozny M, Llinas M, Roos A, Fischer S. Active site labeling with dansyl-glutamyl-glycyl-arginyl chloromethyl ketone demonstrates the full activity of the refolded and purified tissue-type plasminogen activator variant BM 06.022. Applied Biochemistry and Biotechnology 1995; 55: 157-166.
13. Bode C, Smalling R W, Berg G, Burnett C, Lorch G, Kalbfleisch J M, Chernoff R, Christie L G, Feldman R L, Seals A A, Weaver W D, the RAPID II Investigators. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996; 94: 891-898.
14. Kohnert U, Horsch B, Fischer S. A variant of tissue plasminogen activator (t-PA) comprised of the kringle 2 and the protease domain shows a significant difference in the in-vitro rate of plasmin formation as compared to the recombinant human t-PA from transformed Chinese hamster ovary cells. Fibrinolysis 1993; 7: 365-372.
15. Martin U, Bader R, Böhm E, Kohnert U, von Möllendorf E, Fischer S, Sponer G. BM 06.022: A novel recombinant plasminogen activator. Cardiovascular Drug Reviews 1993; 11: 299-311.
16. Martin U, Sponer G, König R, Smolarz A, Meyer-Sabellek W, Strein K. Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis. Blood Coagulation and Fibrinolysis 1992; 3: 139-147.
17. Martin U, Sponer G, Strein K. Evaluation of thrombolytic and systemic effects of novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. J Am Coll Cardiol 1992; 19: 433-440.
18. Martin U, Kohnert U, Hellerbrand K, Stern A, Popp F, Doerge L, Stegmeier K, Müller-Beckmann B, Fischer S. Effective thrombolysis by a recombinant Escherichia coli-produced protease domain of tissue-type plasminogen activator in the rabbit model of jugular vein thrombosis. Fibrinolysis 1996; 10: 87-92.
19. Collen D, Lijnen H R. Tissue-type plasminogen activator. Haemostasis 1986; 16 (suppl 3): 25-32.
20. Gardell S J, Duong L T, Diehl R E, York J D, Hare T R, Register R B, Jacobs J W, Dixon R A F, Friedman P A. Isolation, characterization, and cloning of a vampire bat salivary plasminogen activator. J Biol Chem 1989; 264: 17947-17952.
21. Horrevoets A J G, Smilde A, de Vries C, Pannekoek H. The specific roles of finger and kringle 2 domains of tissue-type plasminogen activator during in-vitro fibrinolysis. J Biol Chem 1994; 269: 12639-12644.
22. Nieuwenhuizen W, Voskuilen M, Trass D W, Hoegee-de Nobel B, Verheijen J H. Kinetics of the tissue-type plasminogen activator mediated activation of plasminogen. The influence of CNBr fibrin(ogen) fragment FCB-2 and different forms of plasminogen. In: Henschen A et al, eds. Fibrinogen - structural variants and interactions. New York: de Gruyter, 1985; 331-342.
23. Wu J H, Diamond S L. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. J Clin Invest 1995; 95: 2483-2490.
24. de Vries C, Veerman H, Pannekoek H. Tissue-type plasminogen activator and its substrate glu-plasminogen share common binding sites in limited plasmin digested fibrin. J Biol Chem 1990; 265: 13547-13552.
25. Onundarson P T, Francis C W, Marder V J. Depletion of plasminogen in-vitro or during thrombolytic therapy limits flbrinolytic potential. J Lab Clin Med 1992; 120: 120-128.
26. Torr S R, Nachowiak D A, Fujii S, Sobel B E. 'Plasminogen steal' and clot lysis. J Am Coll Cardiol 1992; 19: 1085-1090.
27. Sakharov D V, Rijken D C. Superficial accumulation of plasminogen during plasma clot lysis. Circulation 1995; 92: 1883-1890.